Erica Kaye and Dylan Graetz discuss expert recommendations for the conduct and appraisal of qualitative research in haematology
19:40
Presented at ASH: API-CAT post-hoc analysis on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE
9:55
Presented at ASH 2025: EPCORE CLL-1 trial on epcoritamab monotherapy for Richter transformation
14:22
ASH 2025 Preview - Expert Roundtable
22:12
Arnon Kater and Sabina Kersting on the HOVON 158/NEXT STEP phase 2 trial testing a new first-line treatment regimen for chronic lymphocytic leukaemia
24:24
Ruben Mesa on ropeginterferon alfa-2b for hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia
11:45
A panel of the authors on our Lancet Haematology-Lancet Regional Health Western Pacific Series on mature T-cell and natural killer-cell lymphomas
17:58
Lan-Lan Smith, Cheryl Lai, and Daniela Marín discuss the EHA, ICML, and ISTH conferences
19:10
Paolo Strati on off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma
21:49
A panel of the authors on our Adverse Events Series on adverse event reporting in haematological malignancies
40:11
Michael Northend on early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma
15:49
Joanne Verweij and Romy Pothof on fetal and neonatal alloimmune thrombocytopenia
17:47
Helene Schoemans, Elke Stienissen, and Kathy Goris on a consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe
27:06
Dawn Swan on air pollution and venous thromboembolism
15:02
Leslie Skeith on low-dose aspirin for postpartum venous thromboembolism prophylaxis
16:03
Neema Mayor and Caitlin Farrow on impact of patient ethnicity on haematopoeietic cell transplantation outcome in the United Kingdom
17:53
Lancet Haematology 10 year anniversary - meet the editors
47:21
Matteo Della Porta on the phase 3 COMMANDS trial examining luspatercept versus epoetin alfa in patients with lower-risk myleodysplastic syndrome
8:08
Kim Linton on follicular lymphoma
9:48
Judy Truong on ferritin reference levels and iron deficiency
11:17
Johannes Schetelig on remission induction versus immediate allogeneic HSCT for patients with AML
14:11
Banu Aygun on sickle cell anaemia
11:13
Sabine Braat and Katherine Fielding on haemoglobin thresholds to define anaemia
18:06
Elisabeth Schorb on the MARTA phase 2 trial
9:23
Stephan Ehl on paediatric autoimmune lymphoproliferative immunodeficiencies
13:03